Wake Forest University

Novartis Ag

Rijksuniversiteit Groningen

Deborah Meyers

Eugene Roland Bleecker

William B Isaacs

Jianfeng Xu

Patrick C Walsh

Sigun Zheng

David Herrington

David M Herrington

Timothy D Howard

Paul Andrew Whittaker

Dirkje Sjoukje Postma

Gregory A Hawkins

The present invention discloses methods of screening a subject for increased likelihood or risk of certain diseases or disorders. This method comprises detecting the presence or absence of at least one mutation in the MSR1 gene wherein the presence or absence of such mutation indicates an increased risk for certain diseases, such as cancer asthma and/or cardiovascular diseases.

Mutations in the macrophage scavenger receptor 1 gene alter risk of prostate cancer, asthma, and cardiovascular disease

The invention relates to the use of an asthma-associated gene, designated AAGA, the protein molecule encoded by AAGA and related molecules in diagnostic and prognostic screening of patient populations, to polymorphisms in AAGA, and to the use of the protein encoded by AAGA or a variant thereof as a therapeutic target.

Methods for determining the risk of developing asthma characterized by bronchial hyperresponsiveness

A method of screening a subject for increased likelihood of having a favorable response to estrogen replacement therapy comprises detecting the presence of the rare form of at least one estrogen receptor alpha polymorphism in the subject, the presence of the estrogen receptor alpha polymorphism indicating the subject is more likely to have a favorable response to estrogen replacement therapy (e.g., with respect to cardiovascular health, heart disease, and/or HDL levels).

Genetic polymorphisms of estrogen receptor alpha associated with favorable response to hormone replacement therapy

Growing community of inventors

Mocksville, NC, United States of America

Deborah Meyers